Author: Patalon, T.; Gazit, S.; Pitzer, V. E.; Prunas, O.; Warren, J. L.; Weinberger, D. M.
Title: Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine Cord-id: 7f33cu6l Document date: 2021_8_31
ID: 7f33cu6l
Snippet: With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose regimen against infection due to the Delta variant of SARS-CoV-2, using two comple
Document: With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose regimen against infection due to the Delta variant of SARS-CoV-2, using two complementary approaches; a test-negative design and a matched case-control design. We found that 7-13 days after the booster shot there is a 48-68% reduction in the odds of testing positive for SARS-CoV-2 infection and that 14-20 days after the booster the marginal effectiveness increases to 70-84%. Further studies are needed to determine the duration of protection conferred by the third dose and its effect on severe disease.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adequate antibody response: 1, 2, 3, 4
- acute respiratory syndrome and adjustment matching: 1
- acute respiratory syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and long term effectiveness: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and maccabi healthcare services: 1
- acute respiratory syndrome coronavirus and additional protection: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome coronavirus and adequate antibody response: 1, 2, 3, 4
- acute respiratory syndrome coronavirus and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- acute respiratory syndrome coronavirus and long term effectiveness: 1, 2, 3, 4, 5
- acute respiratory syndrome coronavirus and maccabi healthcare services: 1
- additional covariate and logistic regression model: 1
- adjustment matching and logistic regression model: 1
- long term effectiveness and maccabi healthcare services: 1
Co phrase search for related documents, hyperlinks ordered by date